<DOC>
	<DOCNO>NCT00143585</DOCNO>
	<brief_summary>To demonstrate clinical efficacy safety vascular endothelial growth factor ( VEGF165 ) deliver direct myocardial injection NOGA navigational catheter improve myocardial perfusion patient severe angina pectoris conventional PCI CABG either possible ideal.Secondary objective determine effect VEGF gene therapy angina symptom , patient perceive quality life exercise capacity</brief_summary>
	<brief_title>NOGA Angiogenesis Revascularization Therapy : Evaluation RadioNuclide Imaging - The Northern Trial</brief_title>
	<detailed_description>A multicentre , double blind , placebo control trial ass efficacy VEGF promote myocardial angiogenesis patient CCS III-IV angina symptom , treat maximal anti anginal medication amenable ideal candidate conventional revascularization .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Canadian Cardiovascular Class IIIIV angina despite treatment maximal medical therapy LVEF &gt; 20 % Ischemic defect myocardial stress SPECT image NYHA &gt; 2 History diagnosis age relate macular degeneration , retinopathy Atrial fibrillation Primary valvular heart disease Evidence know history cancer past 10 yea Uncontrolled hypertension Liability receive dipyridamole History diagnosis rheumatoid arthritis Recent MI ( within 4 week ) Important iliofemoral peripheral vascular disease , limit catheter access History unexplained gastrointestinal hemorrhage past 5 year LV thrombus visualize either echocardiography contrast LV angiogram Other severe concurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>angiogenesis</keyword>
	<keyword>VEGF</keyword>
</DOC>